Nenocorilant features among the latest industry projects newly into phase 1.
ApexOnco Front Page
Recent articles
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
The group has canned its first-generation project, hoping that a follow-on will reach more patients.
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.
The disappointing Pynnacle trial is set to yield registrational data.
A single but durable stable disease sends the microcap's stock up 730%.
MK-8294 starts phase 1, but its mechanism is anybody's guess.
